Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

Abstract Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials. The irreversible/pan-HER inhibitor neratinib (N) has proven more potent than L. However, the e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jamunarani Veeraraghavan, Carolina Gutierrez, Vidyalakshmi Sethunath, Sepideh Mehravaran, Mario Giuliano, Martin J. Shea, Tamika Mitchell, Tao Wang, Sarmistha Nanda, Resel Pereira, Robert Davis, Kristina Goutsouliak, Lanfang Qin, Carmine De Angelis, Irmina Diala, Alshad S. Lalani, Chandandeep Nagi, Susan G. Hilsenbeck, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9c0763f670574156a633837d6c948965
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models

Ejemplares similares